Helix BioPharma (TSE:HBP) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts and uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Helix BioPharma Corp. has entered into a non-binding letter of intent to acquire the oncology assets of Laevoroc Group, potentially enhancing their immuno-oncology portfolio. The acquisition includes a novel oral chemotherapy formulation and a preclinical immune checkpoint inhibitor, which could simplify cancer treatment and offer new hope for leukemia patients.
For further insights into TSE:HBP stock, check out TipRanks’ Stock Analysis page.
